scispace - formally typeset
Y

Yuji Kaneoka

Publications -  185
Citations -  3733

Yuji Kaneoka is an academic researcher. The author has contributed to research in topics: Hepatocellular carcinoma & Hepatectomy. The author has an hindex of 28, co-authored 175 publications receiving 3101 citations.

Papers
More filters
Journal ArticleDOI

Adjuvant chemotherapy of S-1 versus gemcitabine for resected pancreatic cancer: a phase 3, open-label, randomised, non-inferiority trial (JASPAC 01)

TL;DR: This study found that adjuvant chemotherapy with S-1 can be a new standard care for resected pancreatic cancer in Japanese patients and estimated overall and relapse-free survival using the Kaplan-Meier methods and assessed non-inferiority of S-2 to gemcitabine using the Cox proportional hazard model.
Journal ArticleDOI

Tumor Markers for Hepatocellular Carcinoma: Simple and Significant Predictors of Outcome in Patients with HCC.

TL;DR: The prognosis of patients with HCC can be well discriminated based solely on serum markers, and combination at the time of HCC diagnosis of these three tumor markers and serum albumin and bilirubin levels can be used for HCC staging and further predicts prognosis in patients withHCC.
Journal ArticleDOI

Thirty-six cases of obturator hernia: does computed tomography contribute to postoperative outcome?

TL;DR: The correct preoperative diagnosis of obturator hernia was facilitated by CT of the pelvis, but it has no impact on patient outcome and the intraoperative findings, occurrence of postoperative complications, and overall mortality rates were similar between the two groups.
Journal ArticleDOI

Clinical utility of highly sensitive Lens culinaris agglutinin-reactive alpha-fetoprotein in hepatocellular carcinoma patients with alpha-fetoprotein <20 ng/mL

TL;DR: In patients with AFP <20 ng/mL, measurements of AFP‐L3% by the highly sensitive method before treatment were more useful for diagnosis and prognosis of HCC than by the conventional method.
Journal ArticleDOI

Prognostic significance of simultaneous measurement of three tumor markers in patients with hepatocellular carcinoma

TL;DR: Tumor markers AFP-L3 and DCP appear to represent different features of tumor progression in patients with HCC, and the number of tumor markers present could be useful for the evaluation of tumors progression, prediction of patient outcome, and treatment efficacy.